Cancer Treatment in China: What to Confirm Before You Travel

Direct answer. There is no fixed price for cancer treatment in China, and the fact that a treatment exists here does not mean it is appropriate for you. Before you book travel, a receiving hospital has to review the diagnosis, the pathology, the imaging, the treatment you have already had and your current condition, then put the next step and an itemised estimate in writing. This page is a checklist for international patients and their families. It does not choose a treatment, and it does not replace your oncology team at home.

Key facts

Question	What you can settle before travel	What this page does not decide
Whether to travel	That a department has reviewed enough of the record to say what the visit is for	That surgery, radiotherapy, a medicine or a cell therapy is appropriate
What it costs	A written itemised estimate from the treating hospital, with the currency, who is paid, and what is excluded	A national price, or a budget copied from a website
Which medicine	Whether your biomarkers match a current indication or a trial's entry criteria, in writing	That an approval, including a CAR-T approval, makes you eligible
What to send	Pathology, imaging files, a treatment summary and biomarker reports, plus any slides or tissue the hospital asks for	That a translated summary is enough for every opinion
How long to stay	The hospital's written estimate of the appointment, the tests, the admission and the time to remain nearby	A single number of days for every treatment

What to have in writing before you pay for travel

Ask for these points before you commit to flights, accommodation or a large payment.

• The department and the clinical team that will actually review you. A city's reputation is not a booking.
• What that team has already reviewed, and which tests are still outstanding. State whether the visit is a second opinion, a diagnostic work-up, treatment, screening for a trial, or follow-up.
• An itemised estimate: consultations, pathology review, biomarker testing, medicines, procedure fees, the hospital stay, intensive care if it becomes necessary, management of complications, interpretation, and anything the estimate leaves out. Accommodation and flights are not hospital fees.
• The currency, who is paid, the deposit, and the cancellation and refund terms that apply to an international self-pay patient. A new medicine can carry a different price in different countries. A domestic reimbursement price, or a figure on a public list, does not automatically apply to you. The hospital's written estimate is the figure that matters.
• Who provides language support when you consent, how your documents are stored and transferred, and how an urgent complication, discharge medicines and follow-up with your oncologist at home will be handled.

A hospital plan is not permission to enter the country. The visa guide separates a short transit stay from a visa for a longer visit. Planning the lead time for medical care in China is the page for putting the record, the date and that permission in order. Direct billing and language support is a separate confirmation: an interpreter, and a bill sent to an insurer, exist only when the written scope says so.

An approval is not eligibility

The useful question is not whether a treatment can be found in China. It is whether that treatment fits your cancer and can be given by a qualified team. The answer can turn on the tumour type, the stage, the treatment you have already had, the pathology, the biomarker results, organ function and performance status.

One recent example is satricabtagene autoleucel (satri-cel, also called CT041). Clinical and trade reports dated 22 June 2026 describe an approval by China's National Medical Products Administration for a narrow group: CLDN18.2-positive, HER2-negative advanced gastric or gastroesophageal-junction adenocarcinoma, after at least two prior lines of treatment. One report describes the product as the first CAR-T therapy approved for a solid tumour. That is a reason to check a biomarker. It is not a reason for every person with gastric cancer to travel.

Before you make plans, ask the receiving team to confirm in writing:

• Whether your diagnosis and your biomarker results meet the current indication, or the entry criteria of a trial.
• Whether the pathology has to be repeated, whether the biomarker has to be tested again, or whether a new biopsy is required.
• Which team would give the treatment, and whether that team accepts an international self-pay patient.
• What preparation, cell collection, manufacturing, admission, monitoring and recovery that team itself expects. For a cell therapy, those steps can require a long stay. Availability is not eligibility. The treating hospital decides.
• Which alternatives are appropriate if you are not eligible.

Innovation-drug access in China records what an authorisation does and does not decide. Approval of a medicine is not an appointment, and this site does not sell or source medicines.

Peritoneal disease is a separate question

Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC), and in some programmes pressurised intraperitoneal aerosol chemotherapy (PIPAC) or another local treatment, may be considered for selected people with peritoneal metastases. These procedures are not interchangeable. They are not suitable for every primary tumour or every extent of disease.

Ask the proposed team to explain, in writing:

• Its experience with your primary cancer, for example gastric, colorectal, ovarian or appendiceal cancer, not only with the name of the procedure.
• Why this approach is being proposed, what it is meant to achieve, and what the alternatives are.
• Whether PIPAC, or another local procedure, is actually offered there, and whether it is standard care, an option specific to that programme, or part of a study.
• How likely it is that findings during surgery will change the plan, and what happens if surgery is not appropriate after the review.
• The admission it expects, how complications are managed, whether intensive care is available, and how follow-up works after you return home.

A written specialist opinion before travel can prevent a trip that the findings would not support.

Records first, tickets second

Do not book treatment travel until a receiving hospital has reviewed enough of the record for you to understand the next step. Send a complete package, and keep the originals.

• The pathology report. Ask whether the original slides or the tissue block will be needed.
• Imaging reports and the original DICOM files for recent CT, MRI, PET/CT or ultrasound examinations.
• A treatment summary: surgery, radiotherapy, systemic therapy, dates, response, side effects, and the medicines you take now.
• Genetic and biomarker reports, including the laboratory and the method where you have them. What to verify before genetic testing in China is the checklist for that kind of report. It does not order a test.
• Recent laboratory results and discharge summaries.
• A passport copy and contact details, if the hospital requires them to register the request.

Have the records translated accurately. The hospital may still ask for more material before it can issue an opinion. The time a review takes varies with the file, a pathology review, shipment of tissue and the complexity of the question. Ask for a date for your own file. A brochure that promises one interval for every hospital is not a plan.

Traditional Chinese medicine sits beside the oncology plan

It may be offered as supportive care inside an oncology plan. It is not a replacement for surgery, radiotherapy, systemic therapy or cell therapy.

A 2022 guideline from the Society for Integrative Oncology and the American Society of Clinical Oncology discusses integrative approaches to cancer pain, including acupuncture. Evidence differs by symptom and by intervention. Herbal products can interact with anticancer medicines. Tell both your oncologist at home and the team in China about every herb, supplement and complementary treatment you use.

Decline any provider who presents traditional Chinese medicine, or any other alternative, as a cure for cancer, or who advises you to stop an evidence-based cancer treatment.

How long the stay is, and how you enter

The length of stay depends on the treatment. An opinion based on a complete record is a different trip from major surgery or from cell therapy, which can require preparation, an admission, monitoring and early follow-up.

Before you book, ask the hospital to write down the earliest appointment it can offer, which tests have to be done in China, whether tissue must be sent ahead, the inpatient time it expects, how long you should remain nearby after discharge, and how results, prescriptions and follow-up will be handed back to your team at home.

Entry rules depend on nationality, route, purpose and length of stay. Check the current rule with the Chinese embassy or consulate that handles your application before you pay for travel. The visa guide linked above separates those permissions. It is not an invitation, and this site does not submit visa applications.

Signs to slow down

Be cautious if a provider or a coordinator:

1. Names a firm treatment price, or says you are eligible, before anyone has reviewed the record.
2. Promises a response, a cure, a survival benefit or any other outcome.
3. Presses you to travel before a team has put a plan in writing.
4. Cannot identify the department, the responsible team, or the status of the treatment being proposed.
5. Will not explain what the estimate includes and excludes, who is paid, how cancellation works, or how complications are managed.
6. Asks for hospital fees to be sent to an unrelated intermediary.
7. Markets an alternative therapy as a replacement for oncology treatment.

A personal story can matter to the people in it. It does not predict your outcome. Ask about the team's experience with your diagnosis, the goal of the treatment, and the risks that apply to you.

Where PriumCare fits in China

Where that support is confirmed in your service scope, PriumCare can help you prepare and translate the record, request a written opinion from an appropriate specialist team, ask for a date, and arrange the language support the scope names.

We do not diagnose, we do not treat, and we do not decide which treatment you should receive. We do not promise an outcome. Medical eligibility belongs to the treating hospital. Hospital treatment fees are paid to the hospital. PriumCare does not mark up hospital fees. If a review shows that travel is not appropriate, or that care closer to home is the better course, that is the answer we pass on. For a sudden or worsening emergency, call 120.

Is there a fixed price for cancer treatment in China?

No. The hospital's written, itemised estimate is the figure that matters. A number on a website is not a quote, and a domestic list price does not automatically apply to an international self-pay patient.

Does approval of satricabtagene autoleucel mean I am eligible?

No. The reported indication is narrow: CLDN18.2-positive, HER2-negative advanced gastric or gastroesophageal-junction adenocarcinoma after at least two prior lines of treatment. Your pathology, your biomarkers and the treating team decide. A different gastric cancer is a different question.

Should I book flights before the hospital reviews my records?

No. Send the record first. Book treatment travel when you understand the next step, the tests still required and the written estimate.

Are CRS, HIPEC and PIPAC the same treatment?

No. They are different procedures for selected people with peritoneal metastases. Ask whether the one being proposed is standard care, an option specific to that programme, or part of a study, and what happens if the findings change the plan.

Can traditional Chinese medicine replace chemotherapy or surgery?

No. Supportive care, where a team offers it, sits inside the oncology plan. It does not replace surgery, radiotherapy, systemic therapy or cell therapy. Tell both teams about every herb and supplement. Interactions are a real clinical issue.

What if my oncologist at home needs the papers afterwards?

Ask, before you travel, for the originals, the images and any translation your own clinician says they need. Whether a report is accepted is your clinician's decision.

Does this page choose my treatment?

No. The treating hospital decides after it reviews your record. Bring the advice you already have from home. Do not replace it with this page.

Sources and scope

Reviewed on 11 October 2026. This is a verification checklist for international patients. It is not a medical opinion, and it does not name a hospital.

1. OncLive, report of an NMPA approval of satricabtagene autoleucel for CLDN18.2-positive, HER2-negative advanced gastric or gastroesophageal-junction adenocarcinoma after at least two prior lines, 22 June 2026: https://www.onclive.com/view/china-s-nmpa-approves-first-car-t-cell-therapy-for-cldn18--2-her2-advanced-gastric-gej-adenocarcinoma
2. Society for Integrative Oncology and the American Society of Clinical Oncology, integrative medicine for cancer pain, Journal of Clinical Oncology, 2022: https://ascopubs.org/doi/full/10.1200/JCO.22.01357
3. International consensus statement on patient selection for pressurised intraperitoneal aerosol chemotherapy: https://pubmed.ncbi.nlm.nih.gov/38669779/

Indications, availability, entry rules and prices change. Confirm them with the hospital and the relevant authority before you travel.